Cadent Therapeutics   Report issue

For profit Phase 1 Phase 2
Founded: Cambridge MA United States (2010)
Status: Acquired by Novartis (2020)

Organization Overview

First Clinical Trial
2018
NCT03688685
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Cadent Therapeutics

Active Ingredients

Drugs in Phase 2 Trials (1)

cad-1883 (2 trials)

Drugs in Phase 1 Trials (1)

Plazinemdor (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Ataxia (Phase 2)

Cerebellar Ataxia (Phase 2)

Essential Tremor (Phase 2)

Machado-Joseph Disease (Phase 2)

Schizophrenia (Phase 1)

Spinocerebellar Ataxias (Phase 2)

Spinocerebellar Degenerations (Phase 2)

Tremor (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 2